Usage Examples
- Our signal management SOP sets the EudraVigilance monitoring frequency per active substance, not one default for the whole portfolio.
- We concluded on 14 May that further analysis by the competent authorities was required, so the standalone signal notification is due by 13 June.
- That signal closed before the PSUR data lock point, so it belongs in PSUR sections 15 and 16, not in a standalone notification.
What is Signal Management?
Signal management is the pharmacovigilance process that carries a suspected safety issue from detection through validation, confirmation, prioritisation and assessment to a documented regulatory decision, with every step, date and rationale tracked.
Signal management exists because a medicine's real safety profile only appears once it reaches a population larger, older, sicker and more polypharmacy-exposed than any trial cohort. Spontaneous reports arrive noisy, duplicated and unconfirmed, so regulators require a standing process that converts scattered cases into a decision. In the EU that process is statutory: Regulation (EC) No 726/2004, Directive 2001/83/EC and Commission Implementing Regulation (EU) No 520/2012 all carry signal management provisions.
Signal management covers six defined activities in the EU: signal detection, signal validation, signal confirmation, signal analysis and prioritisation, signal assessment, and recommendation for action. Signal management does not cover routine collection and expedited reporting of individual case safety reports, which sit in GVP Module VI, and it does not cover the risk minimisation measures that follow a decision, which sit in GVP Module V for risk management plans and GVP Module XVI for additional risk minimisation.
Signal management is applied as a documented, auditable cycle, not an ad hoc review. Marketing authorisation holders set and justify a monitoring frequency per active substance, run detection across ICSRs and aggregated data, validate what survives, then pick a route: a variation, inclusion in the PSUR, a standalone signal notification, or an emerging safety issue notification. Every date, decision and rationale is recorded in a tracking system.
Not to be confused with
- Signal detection
- signal detection is the single activity of looking for and identifying signals in data; it is the first step of signal management, not a synonym. Signal management continues through validation, confirmation, prioritisation, assessment and a recorded recommendation for action.
- Pharmacovigilance
- pharmacovigilance is the whole discipline, including case intake, expedited reporting, periodic reports and risk management. Signal management is one process inside it, and the only one whose output is a verdict on whether a risk is new or has changed.
- PSUR
- a PSUR is a periodic deliverable anchored to a fixed data lock point; signal management runs continuously. A validated signal may be carried in the PSUR instead of a standalone notification only when a PSUR is due within 6 months of the assessment being completed.
- RMP
- the risk management plan documents risks already characterised and how they are minimised. Signal management is the process that finds the risk not yet in the RMP and triggers the RMP update.
Signal management obligations attach to the marketing authorisation holder, not to the software vendor or the safety database.
What you must do
- 1Monitor EudraVigilance data at a frequency proportionate to the identified risk, at least every 6 months, and more frequently for active substances in products on the additional monitoring listGVP Module IX (Rev 1) IX.C.3.2
- 2Notify a validated signal or safety issue that meets the definition of an emerging safety issue to the Agency and the competent authorities in writing, no later than 3 working days after establishing that it doesGVP Module IX (Rev 1) IX.C.2
- 3Submit a standalone signal notification no later than 30 days after completing the assessment and concluding that further analysis by the competent authorities is requiredGVP Module IX (Rev 1) IX.C.4.3
- 4Keep an audit trail of signal management activities through a tracking system, recording dates, timeliness, analyses, decisions and rationale for every stepGVP Module IX (Rev 1) IX.B.5
- 5For US-approved applications, promptly review all adverse drug experience information received from any source, foreign or domestic21 CFR 314.80(b)
Common mistakes
Treating signal detection as the whole of signal management
running disproportionality analyses on a schedule and filing the output satisfies nothing. Without validation, confirmation and a recorded decision there is no audit trail, and GVP Module IX classes signal management as a critical process, meaning it is audited at regular intervals and its description must appear in the pharmacovigilance system master file. In the US, 21 CFR 314.80(j) separately requires applicants to keep adverse drug experience records, including raw data and correspondence, for 10 years.
Running one default monitoring frequency across the whole portfolio
GVP Module IX asks each organisation to determine the appropriate frequency for each active substance and to document the frequency and its justification. A blanket "every 6 months" for every product is a documented gap the moment an inspector asks why a newly authorised product under additional monitoring was screened no more often than a 20-year-old generic.
Anchoring the 30-day clock to the wrong date
Day 0 is not the date the drug-event pair surfaced in the detection run. It is the date the marketing authorisation holder concludes that a new or changed risk exists, or that further analysis by the competent authorities is required. Teams that timestamp from the detection output submit late and cannot reconstruct why.
When This Matters
- Our signal management SOP sets the EudraVigilance monitoring frequency per active substance, not one default for the whole portfolio.
- We concluded on 14 May that further analysis by the competent authorities was required, so the standalone signal notification is due by 13 June.
- That signal closed before the PSUR data lock point, so it belongs in PSUR sections 15 and 16, not in a standalone notification.
Frequently Asked Questions
Signal detection is one activity inside signal management, not a synonym for it. GVP Module IX defines the EU signal management process as detection, validation, confirmation, analysis and prioritisation, assessment, and recommendation for action. Detection finds a candidate association; management decides what it means, what to do, and records the rationale.
Related Use Cases
Related Regulatory Intelligence
Related Actions
- Lifecycle Management
Track every sequence operation, amendment, and supplement across the product lifecycle.
- Regulatory Intelligence
Monitor FDA, EMA, ICH, and Health Canada guidance changes across active programs.
- Pharma Regulatory Workflows
NDA, BLA, IND, ANDA, and supplement execution in one workspace.
Sources & References
- EMA/HMA - Guideline on good pharmacovigilance practices (GVP) Module IX: Signal management (Rev 1), EMA/827661/2011 Rev 1
- 21 CFR 314.80 - Postmarketing reporting of adverse drug experiences
- Commission Implementing Regulation (EU) No 520/2012 on the performance of pharmacovigilance activities
- Directive 2001/83/EC on the Community code relating to medicinal products for human use
